CRT grants Geneservice a worldwide exclusive licence to distribute the pSuper RNAi vector system and pRetrosuper vector-based shRNA library generated at the Netherlands Cancer Institute (NKI)
Cancer Research Technology has granted Geneservice a worldwide exclusive licence to distribute the pSuper RNA interference (RNAi) vector system and pRetrosuper vector-based short hairpin RNA (shRNA) library generated by researchers at the Netherlands Cancer Institute (NKI) The pSuper RNAi vector system, developed by Reuven Agami at the Netherlands Cancer Institute (NKI), enables stable and prolonged inhibition of target gene expression in mammalian cells.
The pRetrosuper vector-based library, consisting of almost 24,000 shRNAs complementary to approximately 8000 genes, was developed by Rene Bernards and Roderick Beijersbergen and their team, also based at the NKI.
With an emphasis on oncology-related genes, the library includes a high proportion of candidate drug targets.
The library, contains three target sequences per gene, is sequence validated and is available in single well format, thereby facilitating high-throughput target validation in mammalian cells.
The pRetrosuper platform allows introduction of shRNA expression vectors by transfection and retroviral infection.
Geneservice will be supplying vector, library and individual clones to both academic and commercial parties.
Initially, a kinase-focused subset will be available, which will be followed by distribution of the full-sized library.
Revenues will be shared by Geneservice, the NKI and CRT.
